Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

NCT00670748 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

45

Enrollment

NIH

Sponsor class

Stopped A more highly selected protocol with ESO TCR opened for pts with melanoma

Conditions

Metastatic Melanoma
Metastatic Renal Cell Cancer
Metastatic Cancer

Interventions

BIOLOGICAL: Anti-NY ESO-1 T-cell receptor PBL
DRUG: aldesleukin
DRUG: Cyclophosphamide
DRUG: fludarabine phosphate
BIOLOGICAL: ALVAC NY ESO-1 vaccine

Sponsor

National Cancer Institute (NCI)